A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19

OBJECTIVES: We performed a pilot study of upamostat, a serine protease inhibitor, in outpatients with symptomatic COVID-19 before a pivotal trial. METHODS: SARS-CoV-2 patients with ≥2 moderate-severe symptoms onset within 5 days were randomized to oral upamostat 200 or 400 mg or placebo daily for 14...

Descripción completa

Detalles Bibliográficos
Autores principales: Plasse, Terry F, Delgado, Belkis, Potts, Jeffrey, Abramson, Danielle, Fehrmann, Clara, Fathi, Reza, McComsey, Grace A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762116/
https://www.ncbi.nlm.nih.gov/pubmed/36549549
http://dx.doi.org/10.1016/j.ijid.2022.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762116/
https://www.ncbi.nlm.nih.gov/pubmed/36549549
http://dx.doi.org/10.1016/j.ijid.2022.12.003

Ejemplares similares